medsci-skills 4.1.0

package/skills/write-paper/references/journal_profiles/Chest.md

@@ -0,0 +1,270 @@
+# Journal Profile: CHEST
+
+## Journal Identity
+
+- **Full name**: CHEST (Journal of the American College of Chest Physicians)
+- **Abbreviation**: Chest
+- **Publisher**: Elsevier on behalf of the American College of Chest Physicians (ACCP)
+- **ISSN**: 0012-3692 (print), 1931-3543 (online)
+- **Frequency**: Monthly (12 issues/year)
+- **Impact Factor**: ~9 (JCR 2023), top-tier in pulmonary and critical care
+- **Open Access**: Hybrid (optional OA with APC $4,160; CC BY-NC-ND default, CC BY for mandated funders)
+- **Acceptance rate**: ~15% (approximate)
+- **Peer review**: **Double anonymized** (author identities concealed from reviewers and vice versa); handled by Editorial Manager; dedicated biostatistical review where applicable
+
+---
+
+## Manuscript Types and Word Limits
+
+Word counts exclude abstract, references, figure legends, and tables. Unsolicited submissions are accepted (Y) for the types marked below.
+
+| Type | Unsolicited | Abstract | Body Word Limit | References |
+|------|-------------|----------|-----------------|------------|
+| Original Research | Y | 300 (structured) | 3,200 | 50 |
+| Research Letter | Y | None | 1,000 | 10 |
+| Guidelines and Consensus Statements | Y | 300 (structured) | 4,000 (negotiable) | 150 |
+| Systematic Reviews (no MA) | Y | 250 (structured) | 3,200 | 75 |
+| Scoping Reviews | Y | 250 (structured) | 3,200 | 50 |
+| Narrative Reviews | N (invited) | 250 (structured) | 3,500 | 75 |
+| Special Features | N (invited) | 250 (narrative) | 3,500 | 75 |
+| How I Do It | N (invited) | 250 (unstructured) | 3,000 | 50 |
+| Point/Counterpoint | N (invited) | None | 1,200 (rebuttal 500) | 12 (rebuttal 7) |
+| Editorials | N (invited) | None | 1,000 | 12 |
+| CHEST Commentary | N (invited) | None | 1,000 | 5 |
+| Novel Reports (case) | Y | 150 (narrative) | 750 single / 1,200 multi | 10 |
+| Chest Imaging & Pathology | Y | None | 1,600 | 10 |
+| CHEST Pearls | Y | None | 1,600 | 10 |
+| Ultrasound Corner | Y | None | 1,200 | 10 |
+| Humanities: Case-Based Discussion | N (invited) | 250 (unstructured) | 2,500 | 50 |
+| Humanities: Consilia Historiae | N (invited) | 250 (narrative) | 2,500 | 50 |
+| Humanities: Vantage | N (invited) | None | 1,200 | 7 |
+| Humanities: Exhalations | Y | None | 1,200 | 7 |
+| Humanities: Original Research | Y | 300 (structured) | 3,200 | 50 |
+| Letter to the Editor | Y | None | 400 | 5 |
+
+**Systematic reviews with meta-analysis are submitted as Original Research, not as Systematic Reviews.**
+
+---
+
+## Abstract Requirements
+
+Original Research uses a **6-section structured abstract (300 words max)**:
+
+```
+Background: [Context and knowledge gap]
+Research Question: [Single interrogative sentence — the specific question]
+Study Design and Methods: [Design, setting, participants, exposures/outcomes,
+    analytic approach]
+Results: [Participant flow; primary and secondary findings with effect sizes,
+    95% CIs, and P values]
+Interpretation: [Main conclusion, clinical implications, key limitation]
+Clinical Trial Registration: [Registry name, URL, registration number — RCTs only]
+```
+
+**Critical terminology**: CHEST uses "Research Question" (not "Objective") and "Interpretation" (not "Conclusion"). The Research Question must be phrased as a single interrogative sentence.
+
+Review types (Narrative, Scoping, Systematic, Special Feature) use structured abstracts with review-specific headings; consult the pertinent article-type section in the guidelines.
+
+Research Letters, Editorials, Point/Counterpoint, CHEST Commentary, Correspondence, and most case-based sections do **not** require an abstract.
+
+---
+
+## Required Submission Components (Separate Uploads)
+
+Editorial Manager requires **each** of the following as a separate upload:
+
+1. **Cover Letter**
+2. **Title Page** (author details, IRB approval info, corresponding author full mailing + email address, COI summaries, funding, prior presentation, author contributions)
+3. **Anonymized Manuscript** — main body with references, tables, figure legends, and disclosures; **no author or institutional identifiers anywhere**
+4. **Figure files** (TIFF, JPEG, PDF, or EPS)
+5. **Supplemental material** (e-Tables, e-Figures, e-Appendix numbered consecutively)
+6. **Permissions** (for any reused material)
+7. **Patient consent** (case-based sections and identifiable images)
+8. **Conflict of Interest form** (ICMJE .docx template, one per author)
+
+The anonymized manuscript must remove author names, affiliations, acknowledgments, and any identifying study-site references; IRB approval statements should be anonymized (full committee name + approval number live on the Title Page only).
+
+---
+
+## Required Sections (Original Research)
+
+1. **Introduction** — unlabeled; establish importance, identify gap, state research question
+2. **Study Design and Methods** — ethics/IRB (anonymized in manuscript), design, participants, exposures/outcomes, statistical analysis (pre-specified vs post-hoc distinction required for subgroup analyses)
+3. **Results** — participant flow first; baseline characteristics; primary then secondary outcomes
+4. **Discussion** — key findings, mechanistic context, comparison with prior evidence, strengths, dedicated limitations paragraph
+5. **Interpretation** — brief synthesis (distinct from Conclusion sections used by other journals)
+6. **Acknowledgments** (lives on Title Page for submission): guarantor statement, author contributions (ICMJE criteria), financial/nonfinancial disclosures matching Title Page, role of sponsors
+7. **Declaration of Generative AI and AI-assisted technologies in the writing process** — placed **before References** when applicable
+8. **References**
+
+**Take-Home Point pullout**: Three short sentences (Study Question / Results / Interpretation) provided at submission; published as a pullout.
+
+**Subheading rules**: No more than 8 subheadings per article beyond the main section headings. Each subheading is capped at 5 words (including articles like "a", "the").
+
+---
+
+## Statistical Reporting
+
+- **P values**: Italicized, capitalized ("*P* = .032"); report exact values; use *P* < .001 for very small values.
+- **95% CI required** for primary outcome and key between-group comparisons, in both Abstract and main text.
+- Effect sizes (HR, OR, RR, mean difference) must be accompanied by 95% CI — no P value without an accompanying effect estimate.
+- **Matching language to evidence (HEART Group)**: Observational studies use descriptive language ("we observed a lower risk") rather than causal language ("reduced the risk by"); the latter is reserved for RCTs.
+- **RCTs**: Follow CONSORT checklist; include CONSORT flow diagram as Figure 1; register in an approved public trials registry at or before enrollment; include registration at the end of the abstract.
+- **Observational studies**: Follow STROBE checklist.
+- **Systematic reviews/meta-analyses**: Follow PRISMA; include PRISMA flow diagram as Figure 1; PROSPERO registration strongly encouraged.
+- **Case reports**: Follow CARE.
+- Report statistical software and version.
+- Report missing data handling (complete case, multiple imputation, etc.).
+- Multivariable models: report both adjusted and unadjusted estimates where relevant; specify variable selection method.
+- Subgroup analyses: distinguish pre-specified vs post-hoc; test for interaction.
+
+---
+
+## Figures
+
+- **Formats accepted**: TIFF, JPEG, PDF, EPS.
+- **Color**: Published free of charge (print and online).
+- **AMA/CHEST label conventions**:
+  - "*P*" italicized and capitalized in P values.
+  - Comma separators for numbers with 4+ digits (e.g., 1,234).
+  - Superscript letters (a, b, c) for footnotes.
+  - "Control subjects" not "controls".
+  - "Patients with COPD" not "COPD patients".
+  - Capital "N" for total sample size.
+- **Radiologic/diagnostic images**: Remove all patient-related numbering (test date, MRN) before submission.
+- **Legends**: Provided on a separate page (not on the figure itself); stains and magnifications for photomicrographs required; permissions for republished figures noted in legend; any image manipulation (e.g., splicing) described.
+- **Figure 1 conventions**: CONSORT (RCTs), PRISMA (SRs), STROBE-compatible flow diagrams (cohort/case-control) recommended.
+
+---
+
+## Tables
+
+- Provided as **Word processing documents** (not spreadsheet format, not image).
+- **Maximum 10 columns**; tables exceeding this will not be published.
+- No shading or special symbols; any special formatting (bold, italic) explained in the legend.
+- Self-explanatory with succinct title, column/row headers, legend defining abbreviations, lettered superscript footnotes.
+- Tables comparing prior literature must include a column with lead author last name, year, and numbered citation matching the reference list.
+- Tables may be placed at the end of the main document file.
+
+---
+
+## Supplemental Material (e-Appendix, e-Figure, e-Table)
+
+- Labeled and numbered consecutively: **e-Table 1**, **e-Figure 1**, **e-Appendix 1**, Audio 1, Video 1.
+- Cited in consecutive order in the main text (not interspersed with print-edition material).
+- References in supplemental material are numbered independently from the main text.
+- Manuscript title, author list, and "Supplemental Material" heading must appear at the beginning of each file.
+- Video: .mov, .wmv, .avi, animated .gif, .mpeg, .mp4 (≤10 MB or 5 min); supply a still image for print reference.
+- The main text must stand alone — judicious use of supplements only.
+
+---
+
+## References
+
+- **Superscript numerals** in text, numbered consecutively in order of appearance.
+- If a reference first appears in a table, the in-text callout places the reference number after the table call ("Table 3^27^...").
+- **AMA Manual of Style (11th ed)** formatting.
+- List all authors up to 6; if more than 6, list the first 3 followed by *et al*.
+- Journal names abbreviated per Index Medicus.
+- Article titles in **sentence case**, no quotation marks.
+- Dataset citations allowed; prefix with `[dataset]` in the reference list.
+- References in supplemental material numbered separately.
+
+---
+
+## Common Rejection Reasons
+
+1. **Scope mismatch** — studies without clear relevance to pulmonary, critical care, or sleep medicine.
+2. **Methodological concerns** — inadequate control for confounding, selection bias, immortal time bias, or violations of CONSORT/STROBE/PRISMA reporting.
+3. **Poorly defined research question** — the abstract's Research Question must be a precise, testable, single interrogative sentence.
+4. **Insufficient novelty** — incremental advances over existing guidelines or well-established evidence.
+5. **Statistical problems** — missing CIs, P values without effect estimates, inappropriate tests, multiple-comparisons inflation without correction.
+6. **Under-powered single-center observational work** without adequate external validity or multicenter scope.
+7. **Tobacco-company-funded research** — automatic rejection (see Tobacco Policy below).
+8. **Failure to anonymize** — submission must be fully anonymized in the manuscript file; author details live only in the separate Title Page upload.
+
+---
+
+## Cover Letter
+
+Should include:
+- Article type designation.
+- Statement of novelty (1–2 sentences: what this adds to pulmonary/critical care practice).
+- Confirmation of originality and no dual submission.
+- Confirmation all authors approved the final version.
+- Disclosure summary.
+- Suggested reviewers (required for Original Research; encouraged for other types) — qualified in the subject area, not affiliated with any author's institution.
+- Preprint disclosure (name of server + link) if applicable.
+- Any related prior/concurrent submissions or presentations.
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level**: **Required** when generative AI is used in the writing process.
+- **Permitted scope**: Only to **improve readability and language**; not for substantive analysis, interpretation, or drawing insights from data. Basic grammar/spelling tools are exempt from disclosure.
+- **Disclosure location**: A dedicated section titled **"Declaration of Generative AI and AI-assisted technologies in the writing process"**, placed at the end of the core manuscript file **before the References list**. Statement template: *"During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication."*
+- **Authorship**: AI tools cannot be listed as authors or co-authors, nor cited as authors — authorship implies responsibilities only humans can take.
+- **AI-generated images**: Not explicitly specified in CHEST's author guidelines; Elsevier's publisher-level policy generally requires disclosure of any AI-generated or manipulated figures.
+- **Policy URL**: https://journal.chestnet.org/content/authors (publisher-level policy: Elsevier AI policy for authors)
+
+---
+
+## Tobacco Policy
+
+CHEST **will not consider** research or manuscripts that have been supported by tobacco companies, including their subsidiaries and affiliates. Any tobacco industry funding must be disclosed and will trigger rejection.
+
+---
+
+## Preprints
+
+CHEST considers manuscripts previously posted to preprint servers provided:
+- The preprint is flagged as not peer-reviewed.
+- The cover letter and disclosures note the server name and link to the posting.
+- The final, published version (not the preprint) is cited in any downstream work.
+
+---
+
+## Author Guidelines URL
+
+https://journal.chestnet.org/content/authors
+
+(Submission via Editorial Manager: https://www.editorialmanager.com/chest)
+
+---
+
+## Positioning
+
+**Choose CHEST when**:
+- Pulmonary, critical care, or sleep-medicine research with clear clinical relevance and practice impact.
+- Lung imaging study (CT screening, AI nodule detection, COPD/emphysema quantification) linked to **clinical endpoint** or guideline-relevant outcome.
+- Meta-analysis or systematic review of respiratory interventions, diagnostics, or critical-care management.
+- Guideline-adjacent research (Lung-RADS, Fleischner Society, ACCP/CHEST guideline evidence).
+- Large RCT or prospective cohort in COPD, asthma, ILD, PE, sepsis/ARDS, or sleep apnea.
+
+**Avoid CHEST for**: basic science without translational relevance, purely technical imaging/AI methodology without clinical validation, non-respiratory disease, small single-institution case series (submit as Novel Report only if truly unique).
+
+| Dimension | CHEST | AJRCCM | ERJ |
+|-----------|-------|--------|-----|
+| Society | ACCP (American College of Chest Physicians) | ATS (American Thoracic Society) | ERS (European Respiratory Society) |
+| Scope emphasis | Clinical practice, guidelines, CT screening, critical care | Translational + clinical, mechanistic | Clinical + epidemiology, European policy |
+| Impact factor (2023) | ~9 | ~24 | ~17 |
+| Distinguishing feature | Strong pulmonary-imaging presence; Take-Home Point pullouts; dedicated Humanities section | Highest-impact ATS venue; mechanism-emphasis | ERS flagship; strong cohort/registry work |
+| Peer review | Double anonymized | Single-blind | Single-blind |
+
+---
+
+## CHEST-Specific Nuances (Cheat Sheet for Submission)
+
+- "Interpretation" replaces "Conclusion" in both abstract and main-text section headings.
+- "Research Question" replaces "Objective" in the abstract; must be interrogative.
+- "Study Design and Methods" replaces "Methods" as the section heading.
+- Take-Home Point pullout (3 sentences) is required at submission.
+- Anonymized manuscript + separate Title Page + separate COI form (ICMJE) are mandatory upload components.
+- CONSORT/PRISMA/STROBE/CARE flow diagrams (as applicable) must be Figure 1 for the relevant study type.
+- Supplemental labeled as e-Table/e-Figure/e-Appendix (lowercase "e-", not "S").
+- ICMJE disclosure form (.docx) — do not convert to other formats; signatures not required.
+
+---
+
+<!-- Source verification: Author guidelines text pasted in full by maintainer on 2026-04-20 (equivalent to directly opened guidelines page). ISSN and publisher confirmed against journal homepage https://journal.chestnet.org/. Promoted from private tier to public on 2026-04-20 after reconciliation with official guidelines. -->

package/skills/write-paper/references/journal_profiles/Clinical_Radiology.md

@@ -0,0 +1,160 @@
+# Journal Profile: Clinical Radiology
+
+## Journal Identity
+
+- **Full name**: Clinical Radiology
+- **Abbreviation**: Clin Radiol
+- **Publisher**: Elsevier (Royal College of Radiologists, RCR)
+- **ISSN**: 0009-9260 (print), 1365-229X (online)
+- **Frequency**: Monthly (12 issues/year)
+- **Impact Factor**: ~2.8 (JCR 2023)
+- **Open Access**: Hybrid (optional OA with Elsevier APC)
+- **Acceptance rate**: ~25-30%
+- **Peer review**: Single-blind; typically 2-3 reviewers
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Original Article | 3000 words | 250 words (structured) | 30 | 6 |
+| Review Article | 4000 words | 250 words | 50 | 8 |
+| Technical Note | 1500 words | 150 words (unstructured) | 15 | 4 |
+| Case Report | 1000 words | 100 words (unstructured) | 8 | 4 |
+| Pictorial Review | 3000 words | 200 words | 25 | 12 |
+| Letter to the Editor | 500 words | None | 5 | 1 |
+
+Word counts exclude abstract, references, tables, and figure legends.
+
+---
+
+## Abstract Requirements
+
+**Structured abstract for Original Articles, 250 words maximum:**
+
+```
+AIM: [Study aim — 1 sentence]
+MATERIALS AND METHODS: [Design, population, imaging, analysis]
+RESULTS: [Key findings with statistics]
+CONCLUSION: [Main conclusion — 1-2 sentences]
+```
+
+**Note**: Clinical Radiology uses uppercase heading labels in the abstract.
+
+---
+
+## Required Sections (Original Article)
+
+1. **Introduction** — clinical context, gap, purpose (2-3 paragraphs)
+2. **Materials and Methods**
+   - Study design and ethics
+   - Patient selection
+   - Imaging technique
+   - Image analysis and interpretation
+   - Statistical analysis
+3. **Results**
+4. **Discussion** — including limitations paragraph
+5. **Conclusion**
+
+---
+
+## Statistical Reporting
+
+- Report exact p-values; use p < 0.001 below that threshold.
+- 95% CI for primary outcomes.
+- For diagnostic accuracy: sensitivity, specificity, PPV, NPV, accuracy with 95% CI.
+- Inter-reader agreement where applicable.
+- Effect sizes with clinically meaningful units.
+- Statistical software and version must be identified.
+
+---
+
+## UK-Specific Considerations
+
+### NHS Context
+
+Clinical Radiology serves a largely UK/Commonwealth readership:
+- Reference NHS guidelines and NICE recommendations where applicable
+- Report findings in context of UK radiology practice and referral pathways
+- Acknowledge NHS-specific constraints (scanner availability, contrast protocols)
+
+### RCR Standards
+
+- Reference RCR iRefer guidelines when discussing referral appropriateness
+- Radiation dose reporting: DLP and CTDIvol for CT studies
+- Reference UK national screening programmes where relevant (NHSBSP, lung screening)
+
+### Ethical Reporting
+
+- Health Research Authority (HRA) approval for NHS-based studies
+- IRAS reference number where applicable
+- Caldicott guardian approval for data access studies
+
+---
+
+## Figures
+
+- **Maximum 6 figures/tables** for original articles; **12 for Pictorial Reviews**
+- **Resolution**: 300 DPI minimum
+- **Format**: TIFF, EPS, JPEG, PDF
+- **Color**: Free online
+- **British English**: captions and labels in British English (colour, tumour, centre)
+
+---
+
+## Language
+
+**British English throughout**:
+- colour, tumour, centre, analyse, programme, speciality
+- -ise endings (recognise, standardise, organise)
+- Dates: day month year (11 April 2026)
+
+---
+
+## Common Rejection Reasons
+
+1. **Too specialist for general radiology audience** — Clinical Radiology covers all modalities and body regions; needs broad appeal
+2. **American English** — must use British English throughout
+3. **No UK/Commonwealth relevance** — studies purely from non-UK settings need to address transferability
+4. **Small sample without novelty** — straightforward retrospective studies need strong contribution
+5. **Missing radiation dose data** — expected for CT studies given UK dose awareness culture
+
+---
+
+## Cover Letter
+
+Should include:
+- Relevance to UK radiology practice
+- Key finding summary
+- Statement of originality and non-dual submission
+- Suggested reviewers (optional)
+
+---
+
+## Author Guidelines URL
+
+https://www.clinicalradiologyonline.net/content/authorinfo
+
+---
+
+## Positioning
+
+Clinical Radiology is appropriate when:
+- Radiology study with relevance to UK/Commonwealth practice
+- Multi-modality imaging study with broad clinical applicability
+- AI in radiology with NHS implementation perspective
+- Audit or quality improvement study in radiology
+- Pictorial review of imaging appearances across body regions
+
+Not appropriate for: highly technical AI methodology without clinical context, narrow subspecialty studies better suited to dedicated journals (AJNR, Skeletal Radiology, etc.), non-radiology imaging.
+
+---
+
+## Differentiation from Related Journals
+
+| Dimension | Clinical Radiology | British Journal of Radiology | European Radiology |
+|-----------|-------------------|----------------------------|-------------------|
+| Society | RCR (UK) | BIR (UK/international) | ESR (European) |
+| Scope | General clinical radiology | Radiology + radiation oncology + physics | General radiology (broader) |
+| Language | British English (strict) | British English | British/American English |
+| Impact factor | ~2.8 | ~2.0 | ~5.9 |
+| Emphasis | Clinical practice, NHS context | Physics, technology, oncology | European multicenter, AI |

package/skills/write-paper/references/journal_profiles/Clinical_and_Molecular_Hepatology.md

@@ -0,0 +1,147 @@
+# Journal Profile: Clinical and Molecular Hepatology
+
+## Journal Identity
+
+- **Full name**: Clinical and Molecular Hepatology
+- **Abbreviation**: Clin Mol Hepatol
+- **Publisher**: Korean Association for the Study of the Liver (KASL)
+- **ISSN**: 2287-2728 (print), 2287-285X (online)
+- **Frequency**: Quarterly (January, April, July, October)
+- **Impact Factor**: [TODO: verify at JCR]
+- **Open Access**: Full OA (APC US$1,500 since February 2024; previously US$1,000)
+- **Acceptance rate**: [TODO: verify at journal site]
+- **Peer review**: Blind peer review; ≥2 referees; first decision in approximately 1 month; fast-track option (7-day first decision) available for additional US$1,000
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Original Article | 6,000 (incl. abstract, refs, tables, figure legends) | 250 words structured | 50 | 8 (max 6 panels per figure) |
+| Review Article | 5,000 | [TODO: verify] | [TODO: verify] | 8 |
+| Editorial | 1,500 | — | 20 | 1 |
+| Letter to the Editor | 800 | None | 15 | 1 (max 6 authors) |
+| Correspondence | 1,500 | — | 15 | 1 |
+| Special Topic | 800 | — | 10 | — |
+| Snapshot | 600 | — | 10 | 1 large page figure |
+| Research Letter (online-only) | 1,500 (excl. title/refs/legend) | Structured (Objective / Study Design / Results / Conclusion) — no traditional abstract | 15 | 1 table OR 1 figure; max 7 authors |
+
+---
+
+## Abstract Requirements
+
+Original Article: 250 words maximum, **structured** under four sub-headings:
+
+```
+Background/Aims:
+Methods:
+Results:
+Conclusions:
+```
+
+Followed by 3–5 keywords.
+
+Research Letters: structured four-section format (Objective / Study Design / Results / Conclusion), no abstract per se.
+
+---
+
+## Required Sections (Original Article)
+
+In exact order:
+
+1. **Title page**
+2. **Abstract** (250 words structured, 3–5 keywords)
+3. **Highlights** — mandatory on revised manuscript, encouraged at initial submission. 3–4 sentences summarizing originality and main findings, ≤100 words total, boxed after abstract
+4. **Introduction** — minimum background; do not engage in literature review
+5. **Materials and Methods** (or Patients and Methods) — detail sufficient for replication; cite statistical methods
+6. **Results**
+7. **Discussion** — implications for the field; avoid repetition of results or introduction
+8. **Acknowledgements**
+9. **Conflict of Interest statement** — prior to references
+10. **References** — numbered, superscript Arabic, ≤50
+11. **Tables** (individual sheets, numbered)
+12. **Figure legends** (separate sheet)
+
+**Graphical abstract is MANDATORY** for original articles (separate JPG/TIFF upload; minimum 531×531 px at 600 dpi; final display 200×500 px rectangle).
+
+---
+
+## Statistical Reporting
+
+- Identify and provide references for all statistical methods used (stated explicitly).
+- Sex/gender reporting: distinguish sex (biological) from gender (identity); report sex of participants, animals, or cells and methods used to determine them.
+- Race/ethnicity: define how determined and justify relevance.
+- Exclusive-population studies (e.g., single sex): justify unless self-evident (e.g., prostate cancer).
+- [TODO: verify at journal site] Specific p-value format (significant figures, threshold).
+- [TODO: verify at journal site] 95% CI vs exact p-value preference.
+
+Default — until verified: report exact p-values to 2–3 significant figures; use p<0.001 below that threshold; 95% CI for primary outcomes; state statistical software and version.
+
+---
+
+## Figures
+
+- **Maximum**: 8 figures/tables combined; max 6 panels per figure
+- **Resolution**: ≥300 dpi
+- **Format**: JPG or TIFF
+- **Color**: permitted (authors charged for color figures)
+- **Microscopic images**: must specify staining method and magnification scale
+- **Graphical abstract**: 531×531 px minimum at 600 dpi (mandatory, separate JPG/TIFF file)
+
+---
+
+## Common Rejection Reasons
+
+1. Poor English syntax (journal recommends professional editing pre-submission)
+2. Concurrent or prior publication of the same or closely related data
+3. Missing or inadequate IRB / Declaration of Helsinki statement
+4. Missing graphical abstract for original article submission
+5. Exceeding word / reference / figure limits
+6. Failure to follow structured abstract format (BG/Aims, Methods, Results, Conclusions)
+7. Requiring more than two revision cycles or resubmission beyond 2 months (treated as new submission)
+
+---
+
+## Cover Letter
+
+Should include:
+- Confirmation that neither the submitted material nor portions thereof have been published or are under consideration elsewhere
+- Corresponding author contact (name, address, telephone, fax, email, ORCID)
+- Any prior related publication enclosed for editor review
+- Suggested reviewers (if journal requests; verify at submission portal)
+- Brief highlight of manuscript's significance for the hepatology field
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Required — follows ICMJE guidance as adopted by the journal
+- **Permitted scope:** Disclosure of all AI-assisted technologies used to produce submitted work (large language models, chatbots, image creators). Basic grammar/spelling/reference-check tools are exempt. AI cannot be listed as an author.
+- **Disclosure location:** **Acknowledgements** section, with three mandatory elements: (1) name of AI software, version, manufacturer, and date(s) of use; (2) brief description of how the AI was used and on which portions of the manuscript; (3) confirmation that the author(s) take full responsibility for the integrity of the content generated
+- **AI-generated images:** Must be declared under the same disclosure rule. Citation of AI-generated material as a primary source is not acceptable.
+- **Policy URL:** https://www.e-cmh.org (Instructions for Authors, section "Use of Generative AI and AI-Assisted Technologies in Publication and Research")
+
+---
+
+## Author Guidelines URL
+
+https://www.e-cmh.org/authors/authors.php
+
+Editorial Office: Room A1210, Mapo Trapalace, 53 Mapo-daero, Mapo-gu, 04158, Seoul, Korea; tel +82-2-703-0051; fax +82-2-703-0071; email kasl@kams.or.kr
+Submission portal: https://mc04.manuscriptcentral.com/cmh
+
+---
+
+## Positioning
+
+**When to submit here.** Korean or Asian health-screening / hospital-cohort studies on NAFLD / MASLD / ALD / MetALD, hepatitis B / C natural history, HCC surveillance, KASL-guideline-adherent clinical work, and basic-science translational studies with clear clinical relevance. KASL's flagship journal — strongly preferred for papers that directly cite KASL clinical practice guidelines or Korean national cohort data.
+
+**When NOT to submit here.** Pure methodology/statistics papers without hepatology content; AI-only papers without liver-disease outcome validation; reports of non-liver disease primary outcomes.
+
+| Dimension | Clinical and Molecular Hepatology | Journal of Hepatology (EASL) | Hepatology (AASLD) | Liver International |
+|-----------|----------------------------------|------------------------------|--------------------|---------------------|
+| Society | KASL (Korean) | EASL (European) | AASLD (American) | Wiley, independent |
+| Scope | Basic + clinical hepatology; strong Korean/Asian cohort focus | Basic + clinical hepatology; European / global | Basic + clinical hepatology; American-weighted | Clinical + experimental hepatology; international multi-disciplinary |
+| Impact factor | [verify JCR] | [verify JCR] | [verify JCR] | [verify JCR] |
+| Emphasis | Korean/Asian epidemiology, KASL guideline alignment, 2023 SLD nomenclature | Mechanistic + guideline-defining trials; desk reject aggressive | Mechanistic + AASLD guidance; competitive | Clinical utility, observational + translational |
+| OA model | Full OA | Hybrid | Hybrid | Hybrid |
+| Graphical abstract | Mandatory (original articles) | Mandatory | Mandatory | Optional |